期刊文献+

Current perspectives of viral

下载PDF
导出
摘要 Viral hepatitis represents a major danger to public health,and is a globally leading cause of death.The five liver-specific viruses:Hepatitis A virus,hepatitis B virus,hepatitis C virus,hepatitis D virus,and hepatitis E virus,each have their own unique epidemiology,structural biology,transmission,endemic patterns,risk of liver complications,and response to antiviral therapies.There remain few options for treatment,in spite of the increasing prevalence of viral-hepatitiscaused liver disease.Furthermore,chronic viral hepatitis is a leading worldwide cause of both liver-related morbidity and mortality,even though effective treatments are available that could reduce or prevent most patients’complications.In 2016,the World Health Organization released its plan to eliminate viral hepatitis as a public health threat by the year 2030,along with a discussion of current gaps and prospects for both regional and global eradication of viral hepatitis.Today,treatment is sufficiently able to prevent the disease from reaching advanced phases.However,future therapies must be extremely safe,and should ideally limit the period of treatment necessary.A better understanding of pathogenesis will prove beneficial in the development of potential treatment strategies targeting infections by viral hepatitis.This review aims to summarize the current state of knowledge on each type of viral hepatitis,together with major innovations.
出处 《World Journal of Gastroenterology》 SCIE CAS 2024年第18期2402-2417,共16页 世界胃肠病学杂志(英文版)
基金 Supported by the JSPS Kakenhi Grant,No.JP24K15491.
  • 相关文献

参考文献6

二级参考文献131

  • 1Guan-Min Lai,Sheng-Lei Yan,Cheng-Shyong Chang,Chien-Yu Tsai.Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor[J].World Journal of Gastroenterology,2013,19(8):1318-1321. 被引量:6
  • 2European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection[J]. Journal of Hepatology . 2012 (1)
  • 3Byung Woog Kang,Soo Jung Lee,Joon Ho Moon,Shi-Nae Kim,Yee Soo Chae,Jong Gwang Kim,Yoon-Jin Hwang,Sang-Kyun Sohn.Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review[J]. International Journal of Hematology . 2009 (3)
  • 4K. Ikeda,Y. Shiga,A. Takahashi,T. Kai,H. Kimura,K. Takeyama,H. Noji,K. Ogawa,A. Nakamura,H. Ohira,Y. Sato,Y. Maruyama.Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment[J]. Leukemia & Lymphoma . 2006 (1)
  • 5Patrick Marcellin,Edward Gane,Maria Buti,Nezam Afdhal,William Sievert,Ira M Jacobson,Mary Kay Washington,George Germanidis,John F Flaherty,Raul Aguilar Schall,Jeffrey D Bornstein,Kathryn M Kitrinos,G Mani Subramanian,John G McHutchison,E Jenny Heathcote.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J].The Lancet.2012
  • 6Yi-Hsiang Huang,Liang-Tsai Hsiao,Ying-Chung Hong,Tzeon-Jye Chiou,Yuan-Bin Yu,Jyh-Pyng Gau,Chun-Yu Liu,Muh-Hwa Yang,Cheng-Hwai Tzeng,Pui-Ching Lee,Han-Chieh Lin,Shou-Dong Lee.Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B[J].Journal of Clinical Oncology.2013(22)
  • 7Eric A Engels,Eo Rin Cho,Sun Ha Jee.Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study[J].Lancet Oncology.2010(9)
  • 8C. Pipili,E. Cholongitas,G. Papatheodoridis.Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J]. Aliment Pharmacol Ther . 2014 (1)
  • 9DongmeiJi,JunningCao,XiaonanHong,JunminLi,JianminWang,FangyuanChen,ChunWang,ShanhuaZou.Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B‐cell lymphoma patients who are HBsAg‐negative/?HBcAb‐positive: a multicenter retrospective study[J]. European Journal of Haematology . 2010 (3)
  • 10Chee–Kin Hui,Winnie W.W. Cheung,Hai–Ying Zhang,Wing–Yan Au,Yui–Hung Yueng,Anskar Y.H. Leung,Nancy Leung,John M. Luk,Albert K.W. Lie,Yok–Lam Kwong,Raymond Liang,George K.K. Lau.Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy[J]. Gastroenterology . 2006 (1)

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部